Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1:13:894407.
doi: 10.3389/fphar.2022.894407. eCollection 2022.

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

Lulu Xie  1 , Jingzheng Huang  1 , Linling Wang  1 , Wenrui Ren  1 , Hao Tian  1 , Anhong Hu  1 , Jun Liang  1 , Yuqing Jiao  1 , Yali Li  1 , Qunfang Zhou  1 , Wenjing Zhang  2
Affiliations

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma

Lulu Xie et al. Front Pharmacol. .

Abstract

Background: Lenvatinib combined with a PD-1 inhibitor has obtained a satisfactory antitumor effect in several solid tumors. However, the efficacy and tumor response of lenvatinib with a PD-1 inhibitor in advanced intrahepatic cholangiocarcinoma still need further exploration. Methods: This is a single-arm study for the assessment of the efficacy and tolerability of lenvatinib with a PD-1 inhibitor in intrahepatic cholangiocarcinoma patients who had chemotherapy failure. Efficacy was evaluated based on the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 (RECIST 1.1). Results: A total of 40 patients with advanced intrahepatic cholangiocarcinoma were enrolled after the chemorefractory effect. The median progression-free survival was 5.83 ± 0.76 months. The 3-month and 6-month progression-free survival rates were 80.0% and 32.5%, respectively. The median overall survival was 14.30 ± 1.30 months. The 12-month and 18-month overall survival rates were 61.4% and 34.7%. The 3-month RECIST 1.1 evaluation was that seven patients (17.5%) showed partial response, 23 patients (57.5%) had stable disease, and 10 patients (25.0%) had progressive disease. The objective response rate was 17.5%, and the disease control rate was 75.0%. All the recorded any-grade adverse events inducing treatment termination were controllable, and there were no AE-related deaths. Conclusion: Our study showed that a combination of lenvatinib with the PD-1 inhibitor could be an effective treatment for advanced intrahepatic cholangiocarcinoma after the chemorefractory effect.

Keywords: PD-1 inhibitor; advanced intrahepatic cholangiocarcinoma; chemotherapy failure; combination therapy; lenvatinib.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart of the study. Efficacy and safety of the treatment.
FIGURE 2
FIGURE 2
Tumor percentage changes from the baseline in terms of the target lesion sizes.
FIGURE 3
FIGURE 3
(A) Progression-free survival (PFS) and (B) overall survival (OS) in patients with advanced intrahepatic cholangiocarcinoma after the chemorefractory effect.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Balar A. V., Weber J. S. (2017). PD-1 and PD-L1 Antibodies in Cancer: Current Status and Future Directions. Cancer Immunol. Immunother. 66, 551–564. 10.1007/s00262-017-1954-6 - DOI - PubMed
    1. Chun Y. S., Javle M. (2017). Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control 24, 1073274817729241. 10.1177/1073274817729241 - DOI - PMC - PubMed
    1. Ding Y., Han X., Sun Z., Tang J., Wu Y., Wang W. (2021). Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Front. Oncol. 11, 691380. 10.3389/fonc.2021.691380 - DOI - PMC - PubMed
    1. Esnaola N. F., Meyer J. E., Karachristos A., Maranki J. L., Camp E. R., Denlinger C. S. (2016). Evaluation and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer 122, 1349–1369. 10.1002/cncr.29692 - DOI - PubMed
    1. Finn R. S., Ikeda M., Zhu A. X., Sung M. W., Baron A. D., Kudo M., et al. (2020). Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma. J. Clin. Oncol. 38, 2960–2970. 10.1200/JCO.20.00808 - DOI - PMC - PubMed

LinkOut - more resources